Guanfacine
- Generic Name
- Guanfacine
- Brand Names
- Intuniv, Tenex
- Drug Type
- Small Molecule
- Chemical Formula
- C9H9Cl2N3O
- CAS Number
- 29110-47-2
- Unique Ingredient Identifier
- 30OMY4G3MK
- Background
Guanfacine, or BS 100-141, is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974.
Guanfacine was granted FDA approval on 27 October 1986.
- Indication
Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Gilles de la Tourette's Syndrome, Hypertension, Migraine
A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers
- First Posted Date
- 2009-06-12
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Shire
- Target Recruit Count
- 42
- Registration Number
- NCT00919867
- Locations
- 🇺🇸
Advanced Biomedical Research, Inc., Hackensack, New Jersey, United States
A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers
- First Posted Date
- 2009-05-14
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Shire
- Target Recruit Count
- 38
- Registration Number
- NCT00901576
- Locations
- 🇺🇸
Advanced Biomedical Research, Inc., Hackensack, New Jersey, United States
Modeling Stress-precipitated Smoking Behavior for Medication Development
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Yale University
- Target Recruit Count
- 100
- Registration Number
- NCT00773357
- Locations
- 🇺🇸
Yale Center for Clinical Investigation, Yale University, New Haven, Connecticut, United States
Stress and Medication Effects on Cocaine Cue Reactivity
- Conditions
- Cocaine Related Disorders
- Interventions
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 109
- Registration Number
- NCT00613015
- Locations
- 🇺🇸
Medical University of South Carolina-GCRC, Charleston, South Carolina, United States
Guanfacine to Reduce Stress-Induced Cocaine/Alcohol Craving and Relapse
- Conditions
- Cocaine DependentAlcohol Dependent
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Yale University
- Target Recruit Count
- 75
- Registration Number
- NCT00585754
- Locations
- 🇺🇸
Yale University School of Medicine: Yale Stress Center, New Haven, Connecticut, United States
Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 212
- Registration Number
- NCT00429273
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 661
- Registration Number
- NCT00389675
- Locations
- 🇺🇸
Arkansas Primary Care Clinic, PA, Little Rock, Arkansas, United States
🇺🇸Medical Investigators, Inc., Little Rock, Arkansas, United States
🇺🇸St John's Center for Clinical Research, Jacksonville, Florida, United States
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 849
- Registration Number
- NCT00389779
- Locations
- 🇺🇸
NEA Clinic, Jonesboro, Arkansas, United States
🇺🇸Cardiovascular Research Inst. of Dallas, Dallas, Texas, United States
🇺🇸Central Cardiology Medical Clinic, Bakersfield, California, United States
Guanfacine to Treat Borderline Personality Disorder
- Conditions
- Borderline Personality Disorder
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2006-08-01
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Registration Number
- NCT00358969
- Locations
- 🇺🇸
Mount Sinai Hospital - Mood & Personality Research Group, New York, New York, United States
Pharmacology of Cognition in Schizotypal Personality Disorder
- Conditions
- Schizotypal Personality DisorderPersonality Disorders
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 29
- Registration Number
- NCT00353379
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.